While speech disorder represents an early and prominent clinical feature of atypical parkinsonian syndromes such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), little is known about the sensitivity of speech assessment as a potential diagnostic tool. Speech samples were acquired from 215 subjects, including 25 MSA, 20 PSP, 20 Parkinson's disease participants, and 150 healthy controls. The accurate differential diagnosis of dysarthria subtypes was based on the quantitative acoustic analysis of 26 speech dimensions related to phonation, articulation, prosody, and timing. A semi-supervised weighting-based approach was then applied to find the best feature combinations for separation between PSP and MSA. Dysarthria was perceptible in all PSP and MSA patients and consisted of a combination of hypokinetic, spastic, and ataxic components. Speech features related to respiratory dysfunction, imprecise consonants, monopitch, slow speaking rate, and subharmonics contributed to worse performance in PSP than MSA, whereas phonatory instability, timing abnormalities, and articulatory decay were more distinctive for MSA compared to PSP. The combination of distinct speech patterns via objective acoustic evaluation was able to discriminate between PSP and MSA with very high accuracy of up to 89% as well as between PSP/MSA and PD with up to 87%. Dysarthria severity in MSA/PSP was related to overall disease severity. Speech disorders reflect the differing underlying pathophysiology of tauopathy in PSP and α-synucleinopathy in MSA. Vocal assessment may provide a low-cost alternative screening method to existing subjective clinical assessment and imaging diagnostic approaches.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

INRIA Bordeaux Sud Ouest Talence France

Zobrazit více v PubMed

de Rijk MC, et al. Prevalence of parkinsonism and parkinson’s disease in europe: the europarkinson collaborative study. european community concerted action on the epidemiology of parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1997;62:10–15. PubMed PMC

Hornykiewicz O. Biochemical aspects of parkinson’s disease. Neurology. 1998;51:S2–S9. PubMed

Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354:1771–1775. PubMed

Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy. Neurology. 2003;60:910–916. PubMed

Steele JC, Olszewski J, Richardson JC. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 1964;10:333–359. PubMed

Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004;3:93 – 103. PubMed

Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–676. PubMed PMC

O’Sullivan SS, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131:1362–1372. PubMed

Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Movement Disorders. 2011;26:1083–1095. PubMed

Fanciulli A, Wenning GK. Multiple-system atrophy. N. Engl. J. Med. 2015;372:249–263. PubMed

Meissner WG, et al. Multiple system atrophy: recent developments and future perspectives. Mov. Disord. 2019;34:1629–1642. PubMed

Péran P, et al. Mri supervised and unsupervised classification of parkinson’s disease and multiple system atrophy. Mov. Disord. 2018;33:600–608. PubMed

Huh YE, et al. Differences in early speech patterns between parkinson variant of multiple system atrophy and parkinson’s disease. Brain Lang. 2015;147:14–20. PubMed

Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J. Speech Hearing Res. 1969;12:462–496. PubMed

Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with parkinson’s disease. Behav. Neurol. 1998;11:131–137. PubMed

Kluin KJ, Foster NL, Berent S, Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology. 1993;43:563–563. PubMed

Kluin KJ, Gilman S, Lohman M, Junck L. Characteristics of the dysarthria of multiple system atrophy. Arch. Neurol. 1996;53:545–548. PubMed

Rusz J, et al. Speech disorders reflect differing pathophysiology in parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. J. Neurol. 2015;262:992–1001. PubMed

Duffy, J. R. Motor speech disorders substrates, differential diagnosis, and management (Elsevier, 2013).

Chakraborty N, et al. Dysarthric bengali speech: a neurolinguistic study. J. Postgrad. Medm. 2008;54:268. PubMed

Skodda S, Visser W, Schlegel U. Acoustical analysis of speech in progressive supranuclear palsy. J. Voice. 2011;25:725–731. PubMed

Hlavnička J, et al. Automated analysis of connected speech reveals early biomarkers of parkinson’s disease in patients with rapid eye movement sleep behaviour disorder. Sci. Rep. 2017;7:1–13. PubMed PMC

Brückl M, Ghio A, Viallet F. Measurement of tremor in the voices of speakers with Parkinson’s Disease. Proc. Comp. Sci. 2018;128:47 – 54.

Li, G., Daoudi, K., Klempír, J. & Rusz, J. Linear classification in speech-based objective differential diagnosis of parkinsonism. In International Conference on Acoustics, Speech and Signal Processing, ICASSP, pp 5999–6003, (IEEE, 2018).

Das, B., Daoudi, K., Klempír, J. & Rusz, J. Towards disease-specific speech markers for differential diagnosis in parkinsonism. In International Conference on Acoustics, Speech and Signal Processing, ICASSP, pp. 5846–5850, (IEEE, 2019).

Kowalska-Taczanowska R, Friedman A, Koziorowski D. Parkinson’s disease or atypical parkinsonism? the importance of acoustic voice analysis in differential diagnosis of speech disorders. Brain and Behav. 2020;10:e01700. PubMed PMC

Antolík, T. & Cecile, F. Consonant distortions in dysarthria due to parkinson’s disease, amyotrophic lateral sclerosis and cerebellar ataxia. In Proceedings of the Annual Conference of the International Speech Communication Association, INTERSPEECH, pp. 2152–2156, (ISCA, 2013).

Saxena M, Behari M, Kumaran SS, Goyal V, Narang V. Assessing speech dysfunction using bold and acoustic analysis in parkinsonism. Parkinsonism Rel. Disord. 2014;20:855 – 861. PubMed

Tykalova T, Rusz J, Klempir J, Cmejla R, Ruzicka E. Distinct patterns of imprecise consonant articulation among parkinson’s disease, progressive supranuclear palsy and multiple system atrophy. Brain Lang. 2017;165:1–9. PubMed

Hlavnička, J. et al. Dysprosody differentiate between parkinson’s disease, progressive supranuclear palsy, and multiple system atrophy. In Proceedings of the Annual Conference of the International Speech Communication Association, INTERSPEECH, pp. 1844–1848, (ISCA, 2017).

Rusz J, et al. Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. J. Neurol. 2019;266:1394–1404. PubMed

Miller N, Nath U, Noble E, Burn D. Utility and accuracy of perceptual voice and speech distinctions in the diagnosis of parkinson’s disease, psp and msa-p. Neurodegener. Dis. Manag. 2017;7:191–203. PubMed

Rusz J, et al. Defining speech subtypes in de novo parkinson disease: Response to long-term levodopa therapy. Neurology. 2021;97:2124–2135. PubMed

De Bruin VS, Machado C, Howard RS, Hirsch NP, Lees AJ. Nocturnal and respiratory disturbances in steele-richardson-olszewski syndrome (progressive supranuclear palsy) Postgrad. Med. J. 1996;72:293–296. PubMed PMC

Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC. Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (psp) Parkinsonism Rel. Disord. 2005;11:459–463. PubMed

Clark HM, et al. Motor speech disorders and communication limitations in progressive supranuclear palsy. Am. J. Speech Lang. Pathol. 2021;30:1361–1372. PubMed PMC

Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J. Speech Hearing Res. 1969;12:246–269. PubMed

Duffy, J. R. Motor speech disorders: substrates, differential diagnosis and management (3rd ed.) (St. Louis: Mosby, 2013).

Clark HM, et al. Clinical and imaging characterization of progressive spastic dysarthria. Europ. J. Neurol. 2014;21:368–376. PubMed PMC

Rusz J, et al. Brain volumetric correlates of dysarthria in multiple sclerosis. Brain Langl. 2019;194:58–64. PubMed

Rong P. Automated acoustic analysis of oral diadochokinesis to assess bulbar motor involvement in amyotrophic lateral sclerosis. J. Speech Lang. Hear. Res. 2020;63:59–73. PubMed

Novotny M, et al. Comparison of automated acoustic methods for oral diadochokinesis assessment in amyotrophic lateral sclerosis. J. Speech Lang. Hear. Res. 2020;63:3453–3460. PubMed

Palesi F. Contralateral cortico-ponto-cerebellar pathways reconstruction in humans in vivo: implications for reciprocal cerebro-cerebellar structural connectivity in motor and non-motor areas. Sci. Rep. 2017;7:12841. PubMed PMC

Gandor F, et al. Laryngeal movement disorders in multiple system atrophy: a diagnostic biomarker? Movement Disorders. 2020;35:2174–2183. PubMed PMC

Schalling E, Hartelius L. Speech in spinocerebellar ataxia. Brain Lang. 2013;127:317–322. PubMed

Kim Y, Kent RD, Weismer G. An acoustic study of the relationships among neurologic disease, dysarthria type, and severity of dysarthria. J. Speech Lang. Hear. Res. 2011;54:417–429. PubMed

Hlavnička, J., Růžičková, H., Tykalová, T., Novotny`, M. & Rusz, J. Dysarthria analyzer [computer program]. Beta Version, http://www.dysan.cz/ (2022).

Rusz J, Tykalova T, Ramig LO, Tripoliti E. Guidelines for speech recording and acoustic analyses in dysarthrias of movement disorders. Mov. Disord. 2021;36:803–814. PubMed

Höglinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 2017;32:853–864. PubMed PMC

Postuma RB, et al. Mds clinical diagnostic criteria for parkinson’s disease. Mov. Disord. 2015;30:1591–1601. PubMed

Payan CAM, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the nnipps–parkinson plus scale. PloS One. 2011;6:e22293. PubMed PMC

Rusz J, et al. Speech biomarkers in rapid eye movement sleep behavior disorder and parkinson disease. Ann. Neurol. 2021;90:62–75. PubMed PMC

J., Hlavnicka, J. Automated analysis of speech disorders in neurodegenerative diseases. Ph.D. Thesis, (Faculty of Electrical Engineering, Czech Technical University, Prague, Czechia, 2018).

Hlavnička J, Čmejla R, Klempíř J, Růžička E, Rusz J. Acoustic tracking of pitch, modal, and subharmonic vibrations of vocal folds in parkinson’s disease and parkinsonism. IEEE Access. 2019;7:150339–150354.

Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease

Automated analysis of spoken language differentiates multiple system atrophy from Parkinson's disease

An automatic measure for speech intelligibility in dysarthrias-validation across multiple languages and neurological disorders

Acoustic assessment in mandarin-speaking Parkinson's disease patients and disease progression monitoring and brain impairment within the speech subsystem